GUARDIAN PHARMACY SERVICES INC CLA (GRDN)
Health Care · Pharmacy Services · NYSE
Guardian Pharmacy Services provides specialized pharmacy and medication management solutions for long-term care facilities.
What GUARDIAN PHARMACY SERVICES INC CLA does
Guardian Pharmacy Services operates a network of pharmacies that specialize in providing pharmaceutical services and medication management for long-term care facilities (LTCFs). The company focuses on dispensing medications, providing consulting pharmacy services, and integrating pharmacy operations with the clinical needs of residents in long-term care settings.
Themes: long-term care pharmacy, medication management
Fundamentals
- Price$38.98 as of 2026-10-21 close
- Market cap$2.5B as of 2026-08-03 (share count; price 2026-10-21)
- 1-year return+44.1% 2025-10-21 close $27.05 → 2026-10-21 close $38.98
- P/E37.48 as of 2026-10-21; diluted EPS of the listed share class, as reported in the 10-Q/10-K
- Net margin+3.4% FY2025, SEC XBRL
- Gross margin+20.2% FY2025, SEC XBRL
- ROE+22.6% FY2025, SEC XBRL
- ROICn/a No figure: its interest expense implies more borrowing than the debt lines we read add up to.
- Debt / equityn/a No figure: its filing tags none of the debt lines we read, which is not evidence of zero debt.
- Revenue growth (YoY)+17.9% FY2025, SEC XBRL
- Beta0.69 as of 2026-09-03
- Last reported earnings2026-08-06 SEC EDGAR Form 8-K (Item 2.02)
How GRDN compares in its sector
- price-to-earnings ratiomiddle range 181 covered Health Care peers, as of 2026-10-21
- net profit marginmiddle range 430 covered Health Care peers, as of 2026-09-03
- operating marginmiddle range 417 covered Health Care peers, as of 2026-09-03
- gross marginbottom 10% 189 covered Health Care peers, as of 2026-09-03
- return on equitytop 10% 510 covered Health Care peers, as of 2026-09-03
- free cash flow (absolute dollars, latest fiscal year)middle range 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
GRDN is not currently in any published Top 10 list. Its scores are below.
Top 10 score
49.5 #730 of 1,265 scored · #93 of 145 in Health Care
Growth 76th (revenue growth year over year 17.9%) and trend 64th (a "golden cross" — its 50-day average is above its 200-day); weakest is capital return (18th, consecutive years of dividend increases 0 years).
Scores as of 21 Oct 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 4.
Quarterly results
| Quarter | Revenue | Gross profit | Operating income | Net income | Operating cash flow | Capex |
|---|---|---|---|---|---|---|
| Q2 FY2026 2026-06-30 | $352M | $80M | $21M | $22M | $30M† | — |
| Q1 FY2026 2026-03-31 | $337M | $76M | $18M | $13M | $6M | — |
| Q4 FY2025 2025-12-31 | $398M† | $86M† | $31M† | $21M† | $35M† | $495000† |
| Q3 FY2025 2025-09-30 | $377M | $75M | $16M | $10M | $28M† | $4M† |
| Q2 FY2025 2025-06-30 | $344M | $68M | $13M | $9M | $20M† | — |
| Q1 FY2025 2025-03-31 | $329M | $64M | $13M | $9M | $18M | — |
| Q4 FY2024 2024-12-31 | $339M† | $67M† | $17M† | $12M† | $22M† | $2M† |
| Q3 FY2024 2024-09-30 | $314M | $61M | -$105M | -$122M | -$2M† | $2M† |
† Not filed as a discrete quarter: derived from the company's own year-to-date figures (for example the fourth quarter as the fiscal year minus the first nine months). A derived per-share figure is approximate, because the share count moves within the year.
Balance sheet at 2026-06-30
- Cash and equivalents$90M
- Total debtnot shown the filing tags none of the debt lines we read — not evidence of zero debt
From the company's own SEC 10-Q and 10-K filings (XBRL), re-read every week. Figures in US dollars as filed; informational only — not financial advice.
How GUARDIAN PHARMACY SERVICES INC CLA looks technically
GUARDIAN PHARMACY SERVICES INC CLA (GRDN) is trading 3.5% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 286 trading days ago — a "golden cross", a bullish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 15, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 42, neither overbought (above 70) nor oversold (below 30). It just made a new 20-day low, its first since 2026-09-01, breaking below its recent trading range. It is 19.3% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 3.5% above its 200-day average, the long-term trend line — a longer-term uptrend | +3.5% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $40.81 | $40.81 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $37.66 | $37.66 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing high 15 calendar days ago — the swings before that are what the structure reading is measured on | 15 sessions |
| Wave structure | its recent swings can be read as a completed three-part upward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes above 42.95. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible three-wave upward correction, complete (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 286 trading days ago — a "golden cross", a bullish long-term signal | 286 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 15, below the 25 that marks a real trend) | 14.8 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 42, neither overbought (above 70) nor oversold (below 30) | 41.6 |
|---|---|---|
| Position in its 14-day range | it is trading right at the bottom of its 14-day range ($38.91 to $42.95) — its "stochastic" reading is 2 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 1.7 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish) | 20 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $48.33 | $48.33 |
|---|---|---|
| From the 52-week high | it is 19.3% below its 52-week high (its highest price of the past year) | -19.4% |
| Above the 52-week low | it is 64.3% above its 52-week low (its lowest price of the past year) | +64.3% |
| Below the 52-week high | it is 19.3% below its highest point of the past year | 19.4% |
| Since a 20-day breakout | it just made a new 20-day low, its first since 2026-09-01, breaking below its recent trading range | 1 session |
| Since a 55-day breakout | it made a new 55-day high about 27 trading days ago | 27 sessions |
| All-time high | its highest closing price on record is $48.33 (set on 2026-09-16) | $48.33 |
| Given back of the 52-week move | over the past year its closes ranged ($24.95 to $48.00), and it has given back roughly a third of its rise from last year’s low — 39% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $33.02 to $33.76. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 39.1% |
| From the all-time high | it is 19.3% below its all-time high | -19.4% |
| Nearest price level | it is trading 2.2% below a resistance level at $39.83 — a price it turned at twice since 2026-04-27, most recently on 2026-10-01. Since 2024-10-21 it has 16 such levels below the current price and 2 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +2.2% |
| All-time low | its lowest closing price on record is $14.16 (set on 2024-09-26) | $14.16 |
| Above the all-time low | it is 175.3% above its all-time low | +175.3% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are narrower than usual versus its own recent 6-month history (tighter than about 86% of it) | 14th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $1.69 between its high and its low — about 4.3% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $1.69 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $39.06 and $42.57 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $39.06 – $40.81 – $42.57 |
| Typical daily range (% of price) | its price moves about 4.3% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 4.3% |
| Stretch from the 200-day average | it is trading 0.8 daily ranges above its 200-day average price (3.5% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 0.8 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.68× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
2
| Since a doji | 7 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 7 sessions ago |
|---|---|---|
| Since a hammer | 7 sessions ago, after a stretch of decline, it sold off hard during the session and then closed back near its high — a "hammer", the long lower wick showing the drop was bought back before the close | 7 sessions ago |
Price gaps
2
| Gap at the open | it opened on 2026-10-21 0.7% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -0.7% |
|---|---|---|
| Gap filled | a 9.3% gap up opened on 2026-08-07 has been "filled" 50 sessions ago — price traded back through the level the gap left behind, and it took 2 sessions to close | 50 sessions ago |
Price streaks
1
| Closing streak | it closed lower in its latest session, after a session that did not close lower — a single down day rather than a run | 1 session down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 11.7 percentage points (the stock lost 11.7% while the market lost 0.1%) | -11.7% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 8.0 percentage points (the stock lost 4.7% while the market gained 3.3%) | -8.0% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 1.6 percentage points (the stock gained 8.2% while the market gained 9.8%) | -1.6% |
| vs market, 12 months | over the past 12 months this stock beat the market by 28.9 percentage points (the stock gained 44.1% while the market gained 15.2%) | +28.9% |
Signal agreement
2
| Bullish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, near the bottom of its 14-day range (oversold) — these describe past price behaviour, not a forecast | 3 of 9 |
|---|---|---|
| Bearish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bearish state: a fresh 20-day low, MACD momentum is negative, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 4 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 7.2% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-15 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thin, spanning 1.4% of the share price, which is taken to mean a barrier that gives way easily. | -7.2% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 1% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $38.67 — a volume-weighted average of daily closes over 200 sessions, not a true tick-by-tick VWAP. | +0.8% |
|---|---|---|
| Vs the average paid since it last reported | the price is 7% below the average price paid since it last reported on 2026-08-06 (its 10-Q), so the typical buyer over that stretch is under water. That average is $41.82 — a volume-weighted average of daily closes over 54 sessions, not a true tick-by-tick VWAP. | -6.8% |
Price levels it has turned at before
GRDN last closed at $38.98 on 2026-10-21. Since 2024-10-21 it has turned at 16 prices below its last close and 2 above; the 3 nearest below and the 2 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $39.83 | Resistance | 2.2% above the last close | turned there twice · 2026-04-27 to 2026-10-01 |
| $38.12 | Support | 2.2% below the last close | turned there twice · 2026-03-23 to 2026-06-26 |
| $37.23 | Support | 4.5% below the last close | turned there twice · 2025-11-11 to 2026-07-23 |
| $35.95 | Support | 7.8% below the last close | turned there twice · 2026-03-12 to 2026-09-01 |
| $43.21 | Resistance | 10.8% above the last close | turned there three times · 2026-07-02 to 2026-10-06 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part upward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes above $42.95.
It is the only labelling that fits these swings, though its proportions are not the textbook ones. It was chosen from 3 labellings that survived the rules, counting shorter readings of the same bars.
This reading has stood for 7 trading days, since 2026-10-13.
Read from daily closes as of 2026-10-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Trading below the 50-day moving average · Broke down to a new 20-day low · trendless / choppy (low ADX) · At the bottom of its 14-day range (stochastic below 20) · Trading at this year’s average price paid (anchored VWAP) | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.14 mean, 1=Strong Buy…5=Strong Sell) — 7 analysts
- Mean price target$49.86 range $47.00 – $52.00; median $50.00
Analyst estimates, as of 2026-10-16. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for GRDN
- Consensus EPS estimate$0.3143 next reporting period, as of 2026-10-16
- Estimate change, 30 days-$0.00071 (-0.2%) from $0.315, on 2026-09-11, 35-day window
- Readings revised upward0% of 7 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Government and private efforts to lower pharmaceutical costs and limit pharmacy reimbursements.","Dependence on maintaining and expanding relationships with long-term care facility operators.","Risk of errors in the dispensing or administration of pharmaceuticals and associated liability."]
What changed in the latest 10-Q
AI-assisted comparison of GRDN's 10-Q filed 2026-08-06 against the prior one filed 2026-05-06.
Management's Discussion & Analysis (MD&A)
- Reworded:
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- Notes:
- Both source texts are truncated at the end, so changes beyond the provided text cannot be assessed.
- Only the provided section text was compared; changes in other portions of the filings are not included.
Risk Factors
- Added:
- In the newer filing (filed 2026-08-06), Item 2 'Recent Sales of Unregistered Securities' is replaced with 'None' instead of the conversion disclosure present in the older filing (filed 2026-05-06).
- In the newer filing (filed 2026-08-06), Item 2 'Purchases of Equity Securities by the Issuer or Affiliated Purchasers' is replaced with 'None' instead of the follow-on offering and share repurchase disclosure present in the older filing (filed 2026-05-06).
- In the newer filing (filed 2026-08-06), Exhibit 10.1 is added: 'Eighth Amendment to Third Amended and Restated Loan and Security Agreement, dated as of May 21, 2026, by and among Guardian Pharmacy Services, Inc., the guarantors party thereto, the lenders party thereto, and Regions Bank, as administrative agent and collateral agent', incorporated by reference to Form 8-K, File Number 001-42284, Exhibit 10.1, filed 05/28/2026.
- In the newer filing (filed 2026-08-06), Exhibit 10.2 is added: 'Form of Nonqualified Stock Option Notice of Grant and Award Agreement (Employees) under the Guardian Pharmacy Services, Inc. 2024 Equity and Incentive Compensation Plan'.
- In the newer filing (filed 2026-08-06), Exhibit 10.3 is added: 'Form of Employment Agreement with Senior Vice President Executive Officers'.
- In the newer filing (filed 2026-08-06), the signatory is William Mudd, Senior Vice President and Chief Financial Officer (Principal Financial and Accounting Officer).
- In the newer filing (filed 2026-08-06), the signature date is August 6, 2026.
- Removed:
- In the older filing (filed 2026-05-06), Item 2 'Recent Sales of Unregistered Securities' contained disclosure that on March 28, 2026, 13,521,419 shares of Class B common stock automatically converted into Class A common stock, and on January 30, 2026, 6,018 shares of Class B common stock converted into Class A common stock, with 13,527,437 shares issued under Section 3(a)(9).
- In the older filing (filed 2026-05-06), Item 2 'Purchases of Equity Securities by the Issuer or Affiliated Purchasers' contained disclosure of the Q1 2026 Offering of 1,020,000 shares at $31.00 per share, repurchase of 1,020,000 shares at $29.6825 per share, and a share repurchase table for the three months ended March 31, 2026.
- In the older filing (filed 2026-05-06), Exhibit 10.1 is removed: 'Form of Stock Purchase Agreement, effective as of March 18, 2026', incorporated by reference to Form 8-K, File Number 001-42284, Exhibit 10.1, filed 03/23/2026.
- In the older filing (filed 2026-05-06), the signatory is David K. Morris, Executive Vice President and Chief Financial Officer (Principal Financial and Accounting Officer).
- In the older filing (filed 2026-05-06), the signature date is May 6, 2026.
- Reworded:
- In the newer filing (filed 2026-08-06), the Rule 10b5-1 Plans disclosure states 'During the quarter ended June 30, 2026' whereas in the older filing (filed 2026-05-06) it states 'During the quarter ended March 31, 2026'.
- Notes:
- The Item 1A Risk Factors text itself is substantively identical between the two filings.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales are on record for GRDN — recent Form 4 activity was compensation-related (awards, option exercises, or tax withholding), not open-market buying or selling.
View full insider trading history → View SEC Form 3/4/5 filingsOnly open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding GRDN as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 5,648,463
- Reported value $236,501,148
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 2 increased, 3 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about GRDN's institutional holders → See what each manager we track holds →
Short interest (FINRA)
GRDN had 2,480,634 shares of reported short interest as of the 2026-09-30 FINRA settlement date (delayed, bi-monthly; not real-time).
Short interest as a percent of shares outstanding is not shown for GRDN because we do not hold a verified share count to divide it by. The reported figures above are unaffected.
- Reported short interest (shares) 2,480,634
- Prior settlement (shares) 2,427,722
- Reported change 2.18%
- Days to cover (reported) 3.06
Reported to FINRA as of the 2026-09-30 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- CVS Health (CVS)
- Walgreens Boots Alliance (WBA)
- Omnicare (CVS)
- PharMerica
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare GRDN vs…
Frequently asked questions
What does GUARDIAN PHARMACY SERVICES INC CLA (GRDN) do?
Guardian Pharmacy Services operates a network of pharmacies that specialize in providing pharmaceutical services and medication management for long-term care facilities (LTCFs). The company focuses on dispensing medications, providing consulting pharmacy services, and integrating pharmacy operations with the clinical needs of residents in long-term care settings.
What sector is GUARDIAN PHARMACY SERVICES INC CLA (GRDN) in?
GUARDIAN PHARMACY SERVICES INC CLA (GRDN) is classified in the Health Care sector. Its industry is Pharmacy Services. It trades on NYSE.
Who are GUARDIAN PHARMACY SERVICES INC CLA's (GRDN) competitors?
Notable peers of GUARDIAN PHARMACY SERVICES INC CLA (GRDN) include CVS Health, Walgreens Boots Alliance, Omnicare and PharMerica. This peer set is informational only — not financial advice.
Is GUARDIAN PHARMACY SERVICES INC CLA (GRDN) overbought or oversold right now?
GUARDIAN PHARMACY SERVICES INC CLA (GRDN) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 42, in the neutral middle (as of 2026-10-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on GRDN come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.